Latest Gemtuzumab ozogamicin Stories
The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
MarketResearch.com announces the addition of a new market research report in Biotechnology to their product offering: Antibody Drug Conjugates Market, 2012-2023.
A new study has found Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their disease.
Researchers have discovered a way of eliminating leukemic stem cells, which could lead to new treatments that may help leukemia patients achieve complete remission.
NEW YORK, June 21 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that based on discussions with the U.S.
SILVER SPRING, Md., June 21 /PRNewswire-USNewswire/ -- Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S.
- Large; stout; burly.